About: Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $10.51 (-7.40%)
RNANASDAQAtrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc. Common Stock share price
RNA price activity
Last Price
$10.510
Change (24hr)
-0.84 USD (-7.40%)
Volume
689.62K
Volume (4w avg)
-
Open
$11.20
Day Range
$10.34 - $11.20
Previous Close
$11.35
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
RNA price performance
Delayed
09 Sep, 8:00 pm GMT+0
RNA Market Signals